[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid19":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,47,78,101,129,154,182,206,234,255,281,302,331,351,378,400,418,449,470,496,520,542,565,583,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100438606","a-multimodal-parent-focused-intervention-for-vulnerable-populations-in-the-bronx-100438606",false,"NCT04991467","A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx","CARE","Inclusion Criteria:\n\n* All participants will be primary caregivers who present with moderate level of stress by meeting a severity score of ≥ 14 on the Perceived Stress Scale (PSS)\n* Investigators will allow primary caregivers (e.g., grandmothers and aunts) as it is common in the patient population\n* Clinical cohorts will be active patients in the psychiatric and rheumatology clinics in Montefiore Medical Center (MMC)\n* Frontline health care providers will be those who are required to work on site at Montefiore Medical Center (MMC)\n\nExclusion Criteria:\n\n* Serious psychiatric or substance use difficulty that, in the judgement of the PI, would preclude meaningful participation in a parent intervention\n* Active child abuse\u002Fmaltreatment cases\n* Neurocognitive conditions that may prevent participants from accessing telehealth services\n* Primary language other than Spanish or English\n* Use of the Valera Health app or a smartphone health platform similar to the Valera app","ALL","18 Years",{"count":20,"type":21},390,"ESTIMATED","INTERVENTIONAL",[24],"NA","For caregivers in the Bronx, the pandemic has caused unprecedented psychological distress; in addition to combating social determinants of health (SDOH), these families now face greater financial insecurity and challenges related to their school-aged children. Furthermore, social distancing requirements and limited telehealth resources for Bronx families have posed greater barriers to healthcare. Such parental distress contributes to heightened risk of transgenerational cycles of psychological stress, trauma and maltreatment. The social and economic impacts of the COVID-19 pandemic have had significant consequences for family well-being, putting parents at higher risk of experiencing distress and potentially impairing their ability to provide supportive care to their children. Although children may be less susceptible to the most damaging physical consequences of COVID-19, there are growing concerns regarding the short-and long-term impacts of pandemic-related stressors on children. The marked upheaval of family life over an extended period may make children vulnerable to mental health consequences associated with the public health crisis and infection mitigation efforts. School and childcare closures, unstable financial circumstances, social isolation and lack of support have a disproportionate, cumulative impact on parents and may undermine their capacities to provide support for their children. Importantly, a large body of evidence suggests that parental stress during times of disasters induces psychopathologies in family members including children. Further, high anxiety and depressive symptoms in parents during the pandemic have been associated with higher child abuse potential, whereas greater parental support was associated with lower perceived stress and child abuse potential. In addition to psychological impacts, stress associated with caregiving can interfere with parents' ability to maintain their own health. This multimodal study addresses key strategies to mitigate the psychological and health impact of COVID-19 in parents.",[27,28],"Parenting","Covid19",[30,31,32,33],"COVID","Parental Stress","Social Determinants of Health","Valera","RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":38},"2021-12-17",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Albert Einstein College of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100419780","phase-1-agile-early-phase-platform-trial-for-covid-19-100419780","NCT04746183","AGILE (Early Phase Platform Trial for COVID-19)","AGILE: Seamless Phase I\u002FIIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment","AGILE","Master Protocol Inclusion Criteria:\n\n1. Adults (≥18 years) with laboratory-confirmed\\* SARS-CoV-2 infection (PCR)\n2. Ability to provide informed consent signed by study patient or legally acceptable representative\n3. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in the protocol) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in the candidate-specific trial protocol after the last dose of trial treatment\n\n   * If any CSTs are included in the community setting, the CST protocol will clarify whether patients with suspected SARS-CoV-2 infection are also eligible.\n\nStandard additional criteria that may be applied per CST protocol:\n\nGroup A (severe disease) 4a. Patients with clinical status of Grades 4 (hospitalised, oxygen by mask or nasal prongs), 5 (hospitalised, on non-invasive ventilation, or high flow oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)), as defined by the WHO clinical severity score, 9-point ordinal scale.\n\nGroup B (mild-moderate disease) 4b. Ambulant or hospitalised patients with the following characteristics peripheral capillary oxygen saturation (SpO2) \\>94% RA N.B. The CST protocol inclusion criteria will take precedence over the master protocol inclusion criteria.\n\nCST-2 Inclusion Criteria:\n\nFor the purpose of the EIDD-2801 candidate-specific trial the following inclusion criteria have been amended from the Master protocol to:\n\n1\\. Male or female ≥ 60 years old or ≥50 years old with at least one well controlled comorbidity: cardiovascular disease, chronic lung disease (e.g. COPD, or pulmonary hypertension), immune deficiency (taking the equivalent of 20 mg prednisone daily, chemotherapy, or immune modulating biologic therapies), diabetes (treated with insulin or oral medications), BMI≥30, or hypertension requiring medication with laboratory confirmed SARS-CoV-2 infection (PCR) .\n\n3\\. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use two effective methods of contraception, one of which should be highly effective (as outlined in the protocol). For women, from the first administration of trial treatment, throughout trial and up to 50 days after the last follow up visit (50 days after day 29) and for men with female partners of child bearing potential, from the first administration until 100 days after last follow up visit (100 days after day 29).\n\n4\\. Group B (mild-moderate disease): Ambulant with the following characteristics peripheral capillary oxygen saturation (SpO2) \\>94% RA (NB this differs to the Master Protocol which also includes hospitalised patients in this group).\n\nAdditional criteria specific to this candidate are:\n\n5\\. Has signs or symptoms of COVID-19 that began within 5 days of the planned first dose of study drug.\n\n6\\. Is in generally good health (except for current respiratory infection) and is free of uncontrolled chronic conditions.\n\n7\\. Is willing and able to comply with all study procedures and attending clinic visits through the 4th week.\n\n8\\. Has someone, aged ≥ 16 living in the same household during the dosing period.\n\nCST-6 Additional inclusion criteria:\n\n1. Group A (severe disease). Patients with clinical status of Grades 5 (hospitalised, oxygen by mask or nasal prongs), 6 (hospitalised, on non-invasive ventilation, or high flow oxygen as defined by the WHO Clinical Progression Scale (WHO, 2020)).\n2. Less than or equal to 14 days from onset of COVID-19 symptoms\n\nCST-8 Inclusion Criteria:\n\n1. For the purpose of CST-8, criteria 1 has been amended from the Master Protocol to:\n\n   Adults (≥18 years) outpatients positive lateral flow test at screening or baseline Day 1, who are within 5 days of symptom onset prior to the planned first dose of study drug.\n2. Criteria 3 has been amended from the Master Protocol to:\n\nWomen of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in section 5.5 of the Master Protocol) for the duration of the treatment and for six weeks following the last dose.\n\nAdditional criteria specific to CST-8 are:\n\n* Initial onset of COVID-19 signs\u002Fsymptoms within 5 days prior to the day of randomisation and at least 1 of the current specified COVID-19 signs\u002Fsymptoms (listed on the NHS website) present on the day of randomisation\n* Is willing and able to comply with all study procedures and attending clinic visits\n\nCST-9a Inclusion Criteria:\n\nFor the purpose of CST-9a, criteria 1 has been amended from the Master Protocol to:\n\n1. Adults (\\>\u002F= 18 years of age) with a positive SARS-CoV-2 lateral flow test on screening or Day 1, who are at high risk (as defined in UK DHSC criteria) of progressing to severe COVID-19 disease, within 3 days of symptom onset, with at least one symptom of COVID-19 infection present on the day of randomization and are with mild- moderate disease severity at enrolment.\n\n   Criterion 2 has been amended from the Master Protocol to:\n2. Ability to provide informed consent signed by trial participant or legally acceptable representative and are willing and able to comply with all trial procedures and attending clinic visits\n\n   Criterion 3 has been amended from the Master Protocol to:\n3. Women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP must agree to use two effective methods of contraception, one of which must be highly effective for the duration of the treatment and for 90 Days following the last dose\n\nMaster Protocol Exclusion Criteria:\n\n1. Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>5 times the upper limit of normal (ULN)\n2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2)\n3. Pregnant or breast feeding\n4. Anticipated transfer to another hospital which is not a study site within 72 hours\n5. Allergy to any study medication\n6. Patients taking other prohibited drugs (as outline in CST protocol) within 30 days or 5 times the half-life (whichever is longer) of enrolment\n7. Patients participating in another CTIMP trial\n\nN.B. The CST protocol exclusion criteria will take precedence over the master protocol exclusion criteria.\n\nCST-9a Exclusion Criteria:\n\nExclusion criteria has been amended from master protocol as:\n\n1. Prior SARS-CoV-2 infection \\\u003C90 days before enrolment and\u002For received any COVID-19 vaccine dose \\\u003C90 days before enrolment\n2. Alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN) or Active Liver disease\n3. History or current evidence of cirrhosis\n4. Receiving dialysis or have known moderate to severe renal impairment (defined as CKD stage 4 or 5) or current acute kidney injury on most recent eGFR in the past 6 months\n5. Pregnant or breast feeding\n6. Anticipated transfer to another hospital which is not a trial site within 72 hours\n7. Known allergy to any trial medication\n8. Swallowing difficulties\n9. Currently receiving ALG-097558, Paxlovid, molnupiravir or remdesivir or any SoC therapy for COVID-19 at the time of screening\n10. Received sotrovimab at any point during the current SARS-CoV-2 infection\n11. Oxygen saturations \\\u003C94% on room air\n12. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n13. Participants who have taken or require treatment with a comedication that is a strong CYP450 3A4 inhibitor (atazanavir, clarithromycin, itraconazole, posaconazole, voriconazole, nefazodone, nelfinavir, grapefruit juice, HIV protease inhibitors), strong CYP450 3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) or sensitive substrates of CYP450 2C8 and 2B6 (repaglinide, rosiglitazone, paclitaxel, bupropion) within at least 2 weeks or 5 half-lives (whichever is longer) before the planned first dose of study drug.\n14. Participating in another CTIMP trial\n\nCST-9b Exclusion criteria:\n\n1. Prior SARS-CoV-2 infection diagnosed \\\u003C90 days before enrolment and\u002For received any COVID-19 vaccine dose \\\u003C90 days before enrolment\n2. Alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN) or Active Liver disease\n3. History or current evidence of cirrhosis\n4. Receiving dialysis or have known severe renal impairment defined as CKD stage 5 (an eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m2 at screening, or current acute kidney injury in most recent eGFR in past 6 months.\n5. Pregnant or breast feeding\n6. Anticipated transfer to another hospital which is not a trial site within 72 hours\n7. Known allergy to any trial medication\n8. Swallowing difficulties\n9. Currently receiving ALG-097558, Paxlovid, molnupiravir or remdesivir or any standard of care antiviral therapy for COVID-19 at the time of screening\n10. Received sotrovimab at any point during the current SARS-CoV-2 infection prior to enrolment\n11. Oxygen saturations \\\u003C94% on room air. NOTE: Participants on stable oxygen therapy, including use of NIPPV (non-invasive positive pressure ventilation), for a pre-existing medical condition (e.g., COPD) may be included with oxygen saturation of \\\u003C94% on room air, provided there is no new increased oxygen requirement.\n12. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n13. Participants who have taken or require treatment with a comedication that is a strong CYP450 3A4 inhibitor (atazanavir, clarithromycin, itraconazole, posaconazole, voriconazole, nefazodone, nelfinavir, grapefruit juice, HIV protease inhibitors), strong CYP450 3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) or sensitive substrates of CYP450 2C8 and 2B6 (repaglinide, rosiglitazone, paclitaxel, bupropion) within at least 2 weeks or 5 half-lives (whichever is longer) before the planned first dose of study drug.\n14. Participating in another CTIMP trial within 5 half-lives of the last administered dose of an investigational medicinal product.\n15. Participants eligible for other antiviral treatment according to DHSC criteria, or those otherwise eligible for CST9a.",{"count":56,"type":21},600,[58,59],"PHASE1","PHASE2","The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be based on pre-clinical data, evidence in the clinical setting and GMP capabilities.",[28],[63,64,65,66,67],"SARS coronavirus 2","SARS-CoV-2","Phase I","Phase II","Platform trial","2026-05-27",{"date":70,"type":38},"2026-06-01",{"date":72,"type":38},"2020-07-03",{"date":74,"type":21},"2027-03-31",{"name":76,"class":45},"University of Liverpool",7,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100412558","phase-2-defibrotide-for-the-treatment-of-severe-covid-19-100412558","NCT04652115","Defibrotide for the Treatment of Severe COVID-19","A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.\n3. Radiographic evidence of bilateral pulmonary infiltrates.\n4. A life expectancy of at least 24 hours.\n5. Score of 4-7 on the WHO ordinal scale.\n6. Prophylactic dose anticoagulation is allowed for enrollment into cohort 1. Therapeutic dose anticoagulation for active thrombosis, ECMO, and\u002For continuous renal replacement therapy (CRRT) is allowed for enrollment into cohort 2 if there is no evidence of bleeding after at least 24 hours of anticoagulation.\n7. Patient or surrogate able to provide informed consent\n\nExclusion Criteria:\n\n1. Clinically significant acute bleeding.\n2. Concomitant use of thrombolytic therapy (e.g. t-PA).\n3. Hemodynamic instability, defined as a requirement for \\>1 vasopressor agent for enrollment into cohort 1, and a requirement for \\>2 vasopressor agents for enrollment into cohort 2\n4. Known allergy or hypersensitivity to DF.\n5. Pregnant or lactating.",true,"100 Years",{"count":88,"type":21},42,[59],"The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.",[28],"2026-05-22",{"date":94,"type":38},"2026-05-26",{"date":96,"type":38},"2021-01-01",{"date":98,"type":21},"2027-01-01",{"name":100,"class":45},"Brigham and Women's Hospital",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":85,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100435916","collection-of-sars-cov-2-covid-19-virus-secretions-and-serum-for-countermeasure-development-100435916","NCT04956445","Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development","Population 1:\n\nInclusion Criteria:\n\n1. Positive diagnostic test for COVID-19, influenza A or B virus, non COVID-19 coronavirus, parainfluenza virus, rhinovirus, adenovirus, or metapneumovirus\n2. Patient or legally authorized representative has provided verbal consent \u002F verbal HIPAA (or parental permission form and assent form, as appropriate)\n\nExclusion Criteria:\n\n* None\n\nPopulation 2:\n\nInclusion Criteria:\n\n1. Positive diagnostic test for COVID-19 \\>14 days prior, OR potential to have been exposed to (and mounted antibodies against) COVID-19, OR positive diagnostic test for influenza A or B virus, non COVID-19 coronavirus, parainfluenza virus, rhinovirus, adenovirus, or metapneumovirus\n2. Patient or legally authorized representative has signed informed consent (or parental permission form and assent form, as appropriate)\n\nExclusion Criteria:\n\nPatients with the following criteria:\n\n* Aged under 6 months old\n* Anemia (Hgb \\\u003C7)\n* Platelet \\\u003C80","6 Months","120 Years",{"count":110,"type":21},2000,"OBSERVATIONAL","Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide:\n\n1. Acutely infected patients shed virus that could be of major interest to characterize (viral quantification, characterization of virus shedding -of infective and of non-infective virus) the former reflecting\u002Fpredictive of severity of disease and the latter reflecting extent\u002Fsource of contagiosity.\n2. Convalescent infected patients develop a specific anti-virus antibody response that is (likely) protective and therefore suits the preliminary requirement for the potential benefits of the convalescent patient plasma therapeutic infusion approach. In addition, long term effects of COVID-19 commonly known as long-haulers remains clinically unclear.\n\nThousands of patients have now been diagnosed with COVID-19 in Louisiana (444,000 cases, 10,122 deaths, 2.2% mortality in Louisiana (LA), as of March 2021), and numerous patients are now also complaining of post-acute sequelae of SARS-CoV-2 (PASC). The investigators want to further clarify questions surrounding rational confinement duration and therapeutic approach by collecting plasma of convalescent patients to identify optimal antibody titer by ELISA, specificity of naturally occurring inflammatory (protein\u002Fantibody and RNA) response, and possibly test in vitro antibody neutralization activity.",[28],[64,115,116,117,118],"Data registry","Convalescent plasma","Post COVID-19","Post acute sequelae of COVID-19","2026-05-18",{"date":121,"type":38},"2026-05-19",{"date":123,"type":38},"2020-03-17",{"date":125,"type":21},"2027-12",{"name":127,"class":45},"Tulane University",2,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100425068","phase-2-imaging-immune-activation-in-covid-19-100425068","NCT04815096","Imaging Immune Activation in COVID-19","Inclusion Criteria:\n\n* Age \\>18 years\n* Ability to read and understand written informed consent document\n* Have a recent diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples.\n* \\> 14 days since onset of COVID-19 symptoms (or if no symptoms, from time of initial nucleic acid based diagnostic test).\n* Laboratory evaluations obtained within 60 days prior to entry.\n\n  * Platelet count ≥75,000\u002Fmm3\n  * ANC \\>1000\u002Fmm3\n  * Aspartate aminotransferase (AST) \\\u003C3 x ULN\n  * Alanine aminotransferase (ALT) \\\u003C3 x ULN\n  * Calculated creatinine clearance (CrCl) ≥60 mL\u002Fmin as estimated by the Cockcroft-\n  * Gault equation\n\nExclusion Criteria:\n\n* Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator\n* Participants who are pregnant (female participants of childbearing age will be tested prior to injection of imaging agent at entry visit\u002Finitial visit - positive test will exclude from further participation in the study)\n* Participants who are breastfeeding\n* Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy) must have a negative urine or serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL performed within 24 hours prior to PET imaging. Females of reproductive potential will need to be on 2 forms of birth control (excluding withdrawal or timing methods).\n* Participants who have had prior allogeneic stem cell or solid organ transplant.\n* Screening absolute neutrophil count \\\u003C1,000 cells\u002Fmm3, platelet count \\\u003C75,000 cells\u002Fmm3, hemoglobin \\\u003C 8 mg\u002FdL, estimated creatinine clearance \\\u003C60 mL\u002Fminute, aspartate aminotransferase \\>3 x ULN, alanine aminotransferase \\>3 x ULN.\n* Known SARS-CoV-2 shedding within 5 days of PET imaging.\n* Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry\n* Active systemic autoimmune diseases not related to COVID-19.\n* COVID-19 vaccine prior to the first PET imaging session. Participants may receive COVID-19 vaccination after the first PET imaging session and the optional second PET scan, with the scan being performed at least 2 weeks following the most recent vaccine dose.\n* Prior PET scan or therapeutic radiation within 1 year of study enrollment.",{"count":136,"type":21},80,[59],"This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \\[18F\\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.",[28,140],"SARS-CoV Infection",[142,143],"PET-CT Imaging","[18F]F-AraG","2026-05-05",{"date":146,"type":38},"2026-05-08",{"date":148,"type":38},"2021-04-15",{"date":150,"type":21},"2028-10-01",{"name":152,"class":153},"CellSight Technologies, Inc.","INDUSTRY",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":77},"100553134","dysfunction-of-olfaction-after-covid-19-infection-morphological-and-histomolecular-investigation-100553134","NCT06482138","Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation","Dysfunction of Olfaction After SARS-CoV-2 Infection: Morphological and Histomolecular Investigation of Olfactory Cleft Biopsies and Cytobrushes","DysOSMIC","Inclusion Criteria:\n\n* Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5\u002F10\n* Control group: No OD (TDI-score \\>30.5.)\n\nExclusion Criteria:\n\n* Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations\n* Use of anticoagulation therapy\n* Allergy to local anesthetics","70 Years",{"count":164,"type":21},240,[24],"Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.",[28,168],"Olfactory Dysfunction",[168,170,64,171,172],"COVID-19","Anosmia","Hyposmia","2026-04-30",{"date":175,"type":38},"2026-05-06",{"date":177,"type":38},"2024-01-24",{"date":179,"type":21},"2026-12-31",{"name":181,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100412215","hyperbaric-oxygen-therapy-for-post-covid-19-syndrome-100412215","NCT04647656","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study.","HBOTpCOVID","Inclusion Criteria:\n\n1. Age above 18 years\n2. Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection.\n3. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. History of traumatic brain injury (TBI) or any other non COVID brain pathology\n3. Active malignancy\n4. Substance use at baseline\n5. Severe or unstable physical disorders or major cognitive deficits at baseline\n6. HBOT for any reason prior to study enrolment\n7. Chest pathology incompatible with pressure changes (including moderate to severe asthma)\n8. Ear or Sinus pathology incompatible with pressure changes\n9. An inability to perform an awake brain MRI\n10. Active smoking",{"count":191,"type":21},91,[24],"Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome",[28,195],"Neurocognitive Dysfunction","2026-04-16",{"date":198,"type":38},"2026-04-21",{"date":200,"type":38},"2023-06-01",{"date":202,"type":21},"2027-12-31",{"name":204,"class":205},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":214,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":46},"100419054","institut-de-recherche-cliniques-de-montreal-ircm-post-covid-19-ipco-research-clinic-100419054","NCT04736732","Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic","IRCM Post-COVID-19 (IPCO) Research Clinic: a Multidisciplinary Approach to Evaluate Short and Long-term Complications of COVID-19","IPCO","Inclusion Criteria:\n\n* Any gender, ≥ 18 years old\n* Current resident of Quebec\n* Speaks English or French\n* Have a personal email (to which to send reminders and questionnaire by email )\n\nAND\n\n1 of the following criteria:\n\n• Individuals with at least one COVID-19 positive PCR test, serology or antibody\u002Fantigen test in the last 60 months at day of recruitment. In the absence of a positive COVID-19 test, individuals with symptoms consistent with COVID-19 while living with a person who had a confirmed positive PCR, serology or antibody\u002Fantigen COVID-19 test in the last 60 months at day of recruitment (epidemiologic link).\n\nOR\n\n• Individuals who tested negative for COVID-19 while living with a household member who tested positive for COVID-19 or had a close contact with the viral infection in the context of their work, and never had any COVID-19 related symptoms (presumed COVID negative control group).\n\nOR\n\n• Individuals who don't have any COVID-19 related symptoms actually, have never had tested positive, and have had at least one negative PCR, serology or antibody\u002Fantigen COVID-19 test (presumed COVID negative control group).\n\nOR\n\n• Individuals with an undiagnosed viral infection in the last 60 months at day of recruitment and have persistent symptoms (or not) after the participant has recovered from a viral infection.\n\nExclusion Criteria:\n\n* Any participant not deemed appropriate for enrollment according to the PI\n* Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)",{"count":215,"type":21},650,"While many COVID19 studies are focusing on the immediate biological impact of SARS-CoV2 infection, this multidisciplinary research clinic will inform the global community on its recovery phase across patient cohorts with different degrees of disease severity (asymptomatic, mild \\[non-hospitalized\\], moderate\u002Fsevere \\[hospitalized\\]). The primary objectives are to: 1) evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection and 2) establish a post-COVID-19 biobank. The secondary objective is to develop a model that can predict end-organ complications using epidemiological and clinical data. To complete the objectives, the study will follow 6 patient cohorts: Patients who had previous asymptomatic or mild COVID-19 (no need for oxygen), patients who had previous moderate\u002Fsevere COVID-19 (patients who had an oxygen requirement; moderate=oxygen by nasal cannula; severe=oxygen by high flow nasal cannula, non-invasive positive pressure ventilation or intubation), patients who had COVID-19 but did not develop the post-COVID-19 condition, patients who have never had COVID-19, patients who had flu-like symptoms but did not have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset, and patients with flu-like symptoms and have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset. Patients will be recruited into these cohorts using a strategy that targets the following populations: patients that were hospitalized in centers across Montreal, patients already followed at the IRCM (non-COVID-19) clinic, essential workers, and members of the same household as patients already enrolled in the IPCO clinic research protocol. The IPCO clinic research protocol is the first in the province of Quebec to systematically follow patients post-COVID-19 for short- and long-term complications including end-organ damage while building an extensive biobank that can support future mechanistic research projects.",[28,218],"Long COVID",[220,221,222,223,224,218],"Post-COVID-19 syndrome","COVID-19-related long-term complications","COVID-19 long haulers","Post-COVID-19 condition","Post-acute sequelae of COVID-19","2026-04-13",{"date":227,"type":38},"2026-04-17",{"date":229,"type":38},"2021-02-01",{"date":231,"type":21},"2027-11-04",{"name":233,"class":45},"Emilia Falcone, MD",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":254},"100431324","phase-1-sars-cov-2-ctls-for-mild-to-moderate-covid-19-disease-100431324","NCT04896606","SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease","A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)","INCLUSION CRITERIA\n\n* Age ≥18 to 65 years. AND\n* Proven infection with SARS-CoV-2, defined as detection of SARS-CoV-2 by RT-PCR from nasopharyngeal swab or lower respiratory tract specimen AND\n* Hospitalized at the time of enrollment AND\n* HLA Matched Family Related donor with recent SARS-CoV-2 infection is at least 10 days out from symptom onset. A negative result for COVID-19 by a diagnostic test is not necessary to qualify the donor AND\n* In Stage I or II of disease (mild or moderate) at the time of enrollment (Table 1) AND\n* ONE of the following high-risk conditions:\n\n  * Chronic lung disease not requiring oxygen at home prior to admission (including but not limited to COPD, cystic fibrosis, asthma and sickle cell disease); Underlying heart disease (including hypertension); Patients with an acute myocardial infarction within the last 3 months will require cardiology clearance prior to enrollment; Diabetes mellitus (type I or II) ; Obesity (BMI ≥ 30); Immunosuppressed, based on investigator's assessment.\n\nEXCLUSION CRITERIA:\n\n* Stage III disease (severe) at the time of enrollment (see Table 1)\n* Lack of an identified eligible HLA family related donor\n* No high-risk comorbidities defined in the inclusion criteria (Section 5.1)\n* Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of enrollment\n* Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL Infusion\n* Patients with chronic respiratory failure requiring ventilator support and\u002For oxygen at home prior to admission are excluded\n* Patients with stage D heart failure and\u002For symptoms at rest are excluded\n* Renal function: patients with eGFR or CrCl \\\u003C30 mL\u002Fmin\u002F1.73 m2 will be excluded from study entry.\n* Liver function: Total bilirubin \\> 2 mg\u002Fdl (unless Gilbert's syndrome) OR ALT\u002FAST \\> 5 x ULN\n* Patients currently listed for transplant or potentially eligible to receive organ transplants are excluded from this study\n* Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤50%\n* Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment and for at least 6 weeks after the last dose of SARS-CoV-2 CTLS.\n* Male subjects with female partners of childbearing age who are not willing to use an effective method of birth control during study treatment and for at least 6 weeks after the last dose of SARS-CoV-2 CTLS.\n* Concurrent use of following medications is prohibited:\n\n  * Steroids (\\>2 mg\u002Fkg\u002Fday prednisone equivalent); Immunotherapies within 4 weeks prior to CTL infusion including checkpoint blockade, ATG, Campath, CAR T cells, blinatumomab; Chemotherapy: Tyrosine kinase inhibitors and hydroxyurea must be stopped \\> 72 hours prior to SARS-COV-2-CTL cell infusion; High dose chemotherapy must be stopped \\> 2 weeks prior to SARS-CoV-2-CTLs. High dose chemotherapy is defined in this protocol as any cancer directed therapy causing myelosuppression; Pegylated-asparaginase must be stopped \\> 4 weeks prior to SARS-COV-2-CTL infusion; Intrathecal chemotherapy must be stopped \\> 1 week prior to SARS-COV-2-CTL infusion (e.g. intrathecal methotrexate); Anti T-cell Antibodies: Administration of any T cell lytic or toxic antibody (e.g. alemtuzumab) within 30 days prior to SARS-CoV-2-CTLs is prohibited.","65 Years",{"count":243,"type":21},50,[58,59],"The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of \\>300,000 and climbing.4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19. Virus specific cytotoxic T lymphocytes (CTLs) have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ transplantation. Donor derived CTLs have been shown to be safe and effective against a variety of viruses including CMV, EBV, BK and adenovirus. We hypothesize that SARS-CoV-2 specific CTLs generated from a previously infected family donor will be safe and effective for treatment of COVID-19 in family members with mild to moderate disease.",[28],"2026-04-10",{"date":225,"type":38},{"date":250,"type":38},"2021-09-20",{"date":179,"type":21},{"name":253,"class":45},"New York Medical College",4,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":46},"100390741","influenza-vaccination-acei-and-arb-in-the-evolution-of-sars-cov2-infection-100390741","NCT04367883","Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection","Inclusion Criteria:\n\n* Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.\n\nExclusion Criteria:\n\n* None.\n* For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.",{"count":263,"type":21},3000,"Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.\n\nOther authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.\n\nThe aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.",[266,267,268,269,270,271],"COVID19","Influenza Vaccination","ACE Inhibitors","ARB","Antihistamine Allergy","Amantadine","2026-03-23",{"date":274,"type":38},"2026-03-25",{"date":276,"type":38},"2020-03-01",{"date":278,"type":21},"2028-02-24",{"name":280,"class":45},"Consorci Sanitari de Terrassa",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":46},"100402856","the-effect-of-the-covid-19-pandemic-among-operated-patients-100402856","NCT04525716","The Effect of the Covid-19 Pandemic Among Operated Patients","What Are the Effects of the Covid-19 Pandemic Among Operated Patients? A Hospital Based Cohort in Stockholm, Sweden","Inclusion Criteria:\n\n* Patients that undergo surgical treatment in the Stockholm Region during the study period\n\nExclusion Criteria:\n\n\\-",{"count":289,"type":21},300000,"This project covers several research aims and uses different research methods, such as cohort analyses.",[28,292],"Surgery","2025-11-20",{"date":295,"type":38},"2025-11-26",{"date":297,"type":38},"2020-01-01",{"date":299,"type":21},"2029-12-31",{"name":301,"class":45},"Karolinska Institutet",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100300264","phase-3-the-vitdalize-study-effect-of-high-dose-vitamin-d3-on-28-day-mortality-in-adult-critically-ill-patients-100300264","NCT03188796","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients","The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)","VITDALIZE","Inclusion Criteria:\n\n* ≥18 years\n* Anticipated ICU stay ≥ 48 hours\n* Admission to ICU ≤ 72 hours before screening\n* Severe vitamin D deficiency (≤12 ng\u002Fml or undetectable)\n\nExclusion Criteria:\n\n* Severe gastrointestinal dysfunction (\\> 400 ml residual volume)\u002Funable to take study medication\n* Do not resuscitate (DNR) order\u002Fimminent death\n* hypercalcemia\n* known recent nephrolithiasis, active tuberculosis or sarcoidosis\n* pregnancy\u002Flactation\n* not deemed appropriate by study team\u002Fphysician",{"count":311,"type":21},2400,[313],"PHASE3","In the VITdAL-ICU trial using a large oral dose of vitamin D3 in 480 adult critically ill patients, there was no benefit regarding the primary endpoint hospital length of stay. However, the predefined subgroup with severe vitamin D deficiency (25(OH)D ≤ 12ng\u002Fml) had significantly lower 28-day mortality (36.3% placebo vs. 20.4% vitamin D group, hazard ratio (HR) 0.52 (0.30-0.89), number needed to treat = 6). Therefore, high-dose vitamin D3 in a population of severely vitamin D deficient critically ill patients is a promising and inexpensive intervention that requires confirmatory multicenter studies.\n\nTo date, only 7 interventions (e.g. noninvasive ventilation or prone positioning) have ever demonstrated mortality benefit for Intensive Care Unit (ICU) patients in multicenter trials. In case of benefit, vitamin D treatment in critically ill patients could be immediately implemented worldwide.",[316,317,28],"Critical Illness","Vitamin D Deficiency",[319,320,170],"vitamin D","critical care","2025-11-18",{"date":323,"type":38},"2025-11-21",{"date":325,"type":38},"2017-10-10",{"date":327,"type":21},"2027-03",{"name":329,"class":45},"Medical University of Graz",18,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":340,"studyType":111,"phases":4,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":46},"100402978","covid-19-survivorship-registry-100402978","NCT04527315","COVID-19 Survivorship Registry","Assessment of ICU and Non-ICU Survivors: A Creation of a COVID Survivorship Database","Inclusion Criteria:\n\n* have tested positive for SARS-CoV-2 and discharged from the ICU or,\n* have tested positive for SARS-CoV-2 and have been discharged from hospital or,\n* have tested positive for SARS-CoV-2 but was NOT hospitalized\n* ages 18 and over, and\n* competent and willing to sign informed consent and comply to all aspects of the protocol\n\nCONTROL Inclusion Criteria\n\n* No clinical history of COVID-19,\n* No active clinical symptoms indicative of possible COVID-19,\n* Ages 18 and over,\n* competent and willing to sign informed consent and comply to all aspects of the protocol\n\nExclusion Criteria:\n\n• Participants cannot sign consent\n\nAny individual who meets any of the following criteria will be excluded from participation to the MRI or x-ray portion of the study:\n\n* Participants who are pregnant or currently trying to get pregnant\n* Participants unable to comply with any portion of the protocol (i.e. removing metals prior to entering the MRI scan room) or who have contraindications to MRI scanning (i.e., non-MRI-conditional pacemakers\u002Fdefibrillators, pregnancy, ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants)\n* Persistent symptoms related to COVID-19 (in which case the patient may be re-screened later) As is done for all patients undergoing clinical MRI in our department, each patient will be screened for contraindications to MRI with a routine questionnaire prior to scanning.\n\nCONTROL Exclusion Criteria\n\nPatients with any of the following are excluded from as controls:\n\n* Pace maker\n* Poorly controlled diabetes\n* Poorly controlled Restrictive lung disease\n* Heart failure\n* Parkinson's Disease\n* Hypertension\n* Any diagnosis or history of autonomic neuropathy",{"count":339,"type":21},1500,"12 Months","COVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.",[28],"2025-10-29",{"date":345,"type":38},"2025-10-30",{"date":347,"type":38},"2020-07-17",{"date":125,"type":21},{"name":350,"class":45},"NYU Langone Health",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":368,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":4},"100390606","phase-1-evaluating-avm0703-for-treatment-of-covid-19-or-influenza-mediated-ards-100390606","NCT04366115","Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome","AVM0703","Inclusion Criteria\n\nPatients who meet all of the following criteria will be eligible to participate in the study:\n\n1. Age ≥18 years;\n2. Must have laboratory confirmed COVID-19;\n3. Must have moderate or severe, immediately life-threatening COVID-19 or Influenza (A or B), as follows:\n\n   a. COVID-19 patients with ARDS (Berlin Criteria) as demonstrated by:\n\n   i. Chest radiograph or CT scan showing bilateral opacities not fully explained by effusions, lobar\u002Flung collapse, or nodules;\n\n   ii. Respiratory failure not fully explained by cardiac failure or fluid overload; and\n\n   iii. Impaired oxygenation defined as Moderate (partial pressure of oxygen \\[PaO2\\]:fraction of inspired oxygen \\[FiO2\\] ratio 100 mm Hg to \\\u003C200 mm Hg with positive end-expiratory airway pressure \\[PEEP\\] \\>5 cm H2O) or Severe (PaO2:FiO2 ratio \\\u003C100 mm Hg with PEEP\\>5 cm H2O) on more than 2 arterial blood gases at least 6 hours apart within a 24 hour period;\n\n   b. Influenza (A or B) patients with ARDS (Berlin Criteria) as demonstrated by:\n\n   i. Chest radiograph or CT scan showing bilateral opacities not fully explained by effusions, lobar\u002Flung collapse, or nodules;\n\n   ii. Respiratory failure not fully explained by cardiac failure or fluid overload; and\n\n   iii. Impaired oxygenation defined as Severe (PaO2:FiO2 ratio\\\u003C100 mm Hg with PEEP \\>5 cm H2O) on more than 2 arterial blood gases at least 6 hours apart within a 24 hour period;\n4. Requires invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) despite standard of care rescue measures (eg, prone positioning, and\u002For PEEP ladder, and\u002For inhaled pulmonary vasodilators, and\u002For recruitment maneuvers and\u002For neuromuscular blockade);\n5. Females of childbearing potential must have a negative serum pregnancy test at screening;\n6. Females of childbearing potential and nonsterile males must agree to use medically effective methods of contraception from the time of informed consent through 1 month after study drug infusion; and\n7. Capable of providing informed consent, or if not capable, a legally authorized representative is capable of providing informed consent\n\nExclusion Criteria\n\nPatients who meet any of the following criteria will be excluded from participation in the study:\n\n1. Moribund patient who, in the opinion of the Investigator, is not expected to survive at least 24 hours;\n2. Known hypersensitivity or allergy to the study drug or any of its excipients;\n3. D-dimer level \\>3 times above normal range;\n4. Known gastric or duodenal ulcer;\n5. Uncontrolled type 1 or type 2 diabetes, per judgment of the Investigator;\n6. Active and untreated bacterial, fungal, parasitic, or viral infection other than COVID-19 or Influenza (A or B). Patients with a history of a positive hepatitis B surface antigen and\u002For hepatitis B core antibody must have a negative hepatitis B polymerase chain reaction (PCR) assay result. Patients with history of a positive hepatitis C virus antibody test must have a negative hepatitis C PCR assay result;\n7. Positive testing for tuberculosis during screening;\n8. Known to have received a live vaccine within the previous 1 month;\n9. Immunocompromised patients, defined as those who have received a bone marrow or solid organ transplant on immunosuppressive therapy; or history of human immunodeficiency virus (HIV) infection who have not been taking anti retroviral therapy for at least 6 months before enrollment and\u002For with most recent CD4 count \\\u003C200 cells\u002FmL and\u002For most recent detectable viral load within the previous 6 months;\n10. Moderate to End-stage liver disease (Childs-Pugh Score \\>10);\n11. Dialysis-dependent due to underlying chronic renal disease. Note: patients who require dialysis for treatment of renal failure due to complications of COVID-19 or Influenza (A or B) infection are not excluded from enrollment;\n12. Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to the start of AVM0703 administration, including: angina requiring therapy, symptomatic peripheral vascular disease, New York Heart Association Class III or IV congestive heart failure, left ventricular ejection fraction \\\u003C30%, left ventricular fractional shortening \\\u003C20%, or uncontrolled Grade 3 hypertension (diastolic blood pressure \\[DBP\\] \\>100 mm Hg or systolic blood pressure \\[SBP\\] \\>150 mm Hg) despite antihypertensive therapy.\n\n    Note: patients with heart failure requiring medical support due solely to complications of COVID-19 infection are not excluded from enrollment;\n13. Significant screening 12-lead ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation\u002Fflutter, left bundle-branch block, second degree atrioventricular (AV) block type 2, third-degree AV block, Grade 2 bradycardia, or heart rate corrected QT interval using Fridericia's formula average of triplicate ECGs \\>450 ms;\n14. Manic-depressive disorder, schizophrenia, or a history of severe depression or substance abuse;\n15. Pregnant or breastfeeding;\n16. Concurrent enrollment in any other clinical study involving administration of a novel (ie, unapproved or not considered standard of care) investigational pharmacological agent(s). Concurrent enrollment in observational and device studies and studies involving administration of pharmacological agent(s) approved for other indications or considered emerging standard of care for treatment of COVID-19 (eg, hydroxychloroquine, remdesivir, low-dose dexamethasone), will be allowed if approved by the Sponsor;\n17. Treatment with standard of care or off-label treatments for COVID-19 (eg, remdesivir), not administered as part of a formal clinical study, where the first dose was initiated within 72 hours of study drug start; and\n18. Inability to obtain informed consent from the patient or legally authorized representative.",{"count":360,"type":21},16,[58],"This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.",[364,28,365],"ARDS","Influenza, Human",[364,266,367],"Influenza","NOT_YET_RECRUITING","2025-09-29",{"date":371,"type":38},"2025-10-02",{"date":373,"type":21},"2026-12-01",{"date":375,"type":21},"2032-03-01",{"name":377,"class":153},"AVM Biotechnology Inc",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":386,"minAge":18,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":46},"100440310","covid-19-international-drug-pregnancy-registry-100440310","NCT05013632","COVID-19 International Drug Pregnancy Registry","COVID-19 International Drug Pregnancy Registry (COVID-PR)","COVID-PR","Inclusion Criteria:\n\n* Pregnant or recently pregnant (up to 30 days after the end of pregnancy) at time of enrollment\n* Age ≥18 years at time of enrollment\n* With mild to severe COVID-19 during pregnancy\n* Either\n\n  * Treated for COVID-19 with at least one of the medications included in Table 1 during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP or\n  * Hospitalized and did not receive any pharmacological treatment specifically indicated for mild, moderate, or severe COVID-19 during pregnancy\n* Resident of a country where a Central Institutional Review Board (IRB) or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study\n* Signed the informed consent form and submitted the baseline module \"COVID-19 Medications During This Pregnancy\"\n\nExclusion Criteria:\n\n● \\\u003C18 years of age","FEMALE","50 Years",{"count":110,"type":21},"The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.",[28],"2025-09-22",{"date":393,"type":38},"2025-09-26",{"date":395,"type":38},"2021-12-01",{"date":397,"type":21},"2027-09-30",{"name":399,"class":153},"Pregistry",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":85,"sex":386,"minAge":18,"maxAge":387,"enrollmentInfo":408,"targetDuration":410,"studyType":111,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":46},"100416626","covid-19-vaccines-international-pregnancy-exposure-registry-100416626","NCT04705116","COVID-19 Vaccines International Pregnancy Exposure Registry","COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)","C-VIPER","Inclusion criteria:\n\nVaccinated population:\n\n* Pregnant at time of enrollment\n* Age ≥18 years at time of enrollment\n* Signed the informed consent form and submitted the baseline module \"COVID-19 Vaccination During This Pregnancy\"\n* Received at least one dose of a COVID-19 vaccine during pregnancy or within the 30 days prior to the first day of the LMP\n* Resident of a country where a Central Institutional Review Board (IRB) or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study\n\nEfforts will be made to obtain documentary evidence of COVID-19 vaccination.\n\nComparison population:\n\n* Pregnant at time of enrollment\n* Age ≥18 years at time of enrollment\n* Signed the informed consent form and submitted the minimum required data in the initial baseline questionnaire\n* Have not received a COVID-19 vaccine during pregnancy or within the 30 days prior to the first day of the LMP\n* Resident of a country where a Central IRB or Ethics Committee provided approval to conduct the study or clearance that approval is not required to conduct the study\n\nExclusion criteria:\n\n* Not pregnant at time of enrollment\n* Age \\\u003C18 years at time of enrollment",{"count":409,"type":21},6000,"21 Months","The objective of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is to evaluate obstetric, neonatal, and infant outcomes among women vaccinated during pregnancy with a COVID-19 vaccine.\n\nSpecifically, the C-VIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestational diabetes, gestational hypertension, intrauterine growth restriction, postpartum hemorrhage, fetal distress, uterine rupture, placenta previa, chorioamnionitis, Caesarean delivery, COVID-19), neonatal outcomes (major congenital malformations, low birth weight, neonatal death, neonatal encephalopathy, neonatal infections, neonatal acute kidney injury, preterm birth, respiratory distress in the newborn, small for gestational age, stillbirth, COVID-19), and infant outcomes (developmental milestones \\[motor, cognitive, language, social-emotional, and mental health skills\\], height, weight, failure to thrive, medical conditions during the first 12 months of life, COVID-19) among pregnant women exposed to single (homologous) or mixed (heterologous) COVID-19 vaccine brand series from 30 days prior to the first day of the last menstrual period to end of pregnancy and their offspring relative to a matched reference group who received no COVID-19 vaccines during pregnancy.",[28],{"date":393,"type":38},{"date":415,"type":38},"2021-06-01",{"date":179,"type":21},{"name":399,"class":153},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":427,"studyType":111,"phases":4,"briefSummary":428,"conditions":429,"keywords":433,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":448},"100416676","kidney-injury-in-times-of-covid-19-kidcov-100416676","NCT04705766","KIDney Injury in Times of COVID-19 (KIDCOV)","The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY","KIDCOV","Inclusion Criteria:\n\n* Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC\n* Age 18 years or older at enrollment\n* Race\u002Fethnicity, sex, age, and phone and\u002For home\u002Femail address provided\n\nExclusion Criteria:\n\n* Failure of a candidate participant to give written informed consent to comply with the study protocol\n* Hospitalization up to 4 weeks after SARS-CoV-2 test\n* History of kidney transplant\n* History of dialysis",{"count":110,"type":21},"1 Year","There is an unmet need to evaluate the impact of sub-clinical\u002Fmild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race\u002Fethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race\u002Fethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.",[140,28,430,431,432],"Corona Virus Infection","Acute Kidney Injury","Kidney Injury",[64,431,170,434,435,436,437,438,439,432],"Coronaviurs","COVID-19 Infection","SARS-CoV-2 infection","Coronavirus infection","COVID-19 and Acute Kidney Injury","SARS-CoV-2 & Kidney Injury Risk Factors","2025-07-24",{"date":442,"type":38},"2025-07-28",{"date":444,"type":38},"2021-03-01",{"date":327,"type":21},{"name":447,"class":45},"University of California, San Francisco",3,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":456,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":466,"leadSponsor":468,"locationsCount":46},"100426803","corona-in-the-saarland-100426803","NCT04837755","CORONA in the Saarland","CORSAAR","Inclusion Criteria:\n\nall form of COVID-19 including long-COVID-19\n\nExclusion Criteria:\n\n\\-","0 Years","110 Years",{"count":459,"type":21},300,"The CORSAAR study is an observational, prospective study to investigate the natural biology of COVID-19",[28],"2025-05-21",{"date":464,"type":38},"2025-05-25",{"date":276,"type":38},{"date":467,"type":21},"2025-12-31",{"name":469,"class":45},"Universität des Saarlandes",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":46},"100413642","inspiratory-effort-in-covid-19-100413642","NCT04666246","Inspiratory Effort in COVID-19","Inspiratory Effort Assessment in Patients With COVID-19 Pneumonia Undergoing Non Invasive Respiratory Support","PERSIA","Inclusion Criteria:\n\n* COVID-19\n* Acute respiratory failure undergoing non-invasive respiratory support\n\nExclusion Criteria:\n\n* Need for immediate endotracheal intubation\n* Chronic respiratory diseases","80 Years",{"count":480,"type":21},40,"This study aims at assessing esophageal pressure in patients with acute respiratory failure due to COVID-19 undergoing non invasive respiratory support.",[483,28],"Acute Respiratory Failure",[485,486,487,170],"Acute respiratory failure","Esophageal pressure","Non invasive respiratory support","2025-04-24",{"date":490,"type":38},"2025-04-25",{"date":276,"type":38},{"date":493,"type":21},"2030-02-01",{"name":495,"class":45},"University of Modena and Reggio Emilia",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":504,"targetDuration":107,"studyType":111,"phases":4,"briefSummary":505,"conditions":506,"keywords":507,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":46},"100409072","cardiovascular-disease-progression-and-prognosis-in-covid-19-100409072","NCT04606732","CardioVascular Disease Progression and Prognosis in COVID-19","Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia","CVP-Covid19","Inclusion Criteria:\n\nhospitalization for COVID-19\n\nExclusion Criteria:\n\nage \\\u003C18 years",{"count":110,"type":21},"The CVP-COVID19 registry is both a retrospective and prospective study design in order to identify predictors of cardiovascular disease progression and mortality for COVID-19. The registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2 admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The study does not test any new diagnostic or therapeutic approach. Patients are treated according to good clinical practice. Patients characteristics, including medical history (with particular attention to cardiovascular and pneumological risk factors), features of physical examination, results laboratory and radiological tests and treatments (pre- and in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate and propensity) are performed in order to identify factors associated with disease progression. Primary endpoint: mortality.",[28],[508,509,64,510,511],"Cardiovascular Diseases","Pneumonia, Viral","Covid-12","ACE receptor","2025-03-24",{"date":514,"type":38},"2025-03-27",{"date":516,"type":38},"2020-09-20",{"date":467,"type":21},{"name":519,"class":45},"University of Bologna",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":46},"100409419","lung-function-exercise-capacity-and-serology-responses-in-patients-with-covid-19-100409419","NCT04611243","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","Inclusion Criteria: Patients who have been discharged from hospital following treatment for COVID-19 -\n\nExclusion Criteria: Unwilling to be follow up\n\n\\-",{"count":527,"type":21},700,"(a) Objectives\n\n1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years.\n2. To assess the longevity of the serology response to SARS-CoV2.\n3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model\n4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines.\n5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)",[530,531,532,28],"Lung Function","Exercise Capacity","Quality of Life","2024-08-19",{"date":535,"type":38},"2024-08-21",{"date":537,"type":38},"2020-05-22",{"date":539,"type":21},"2026-02-17",{"name":541,"class":45},"Chinese University of Hong Kong",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":550,"enrollmentInfo":551,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":46},"100406980","prevalence-and-outcome-of-sars-cov-2-infection--covid-19-in-transplant-recipients-the-covitra-study-100406980","NCT04579471","Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study","Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study","COVITRA","Inclusion Criteria:\n\n* all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent\n\nExclusion Criteria:\n\n* age under 18 years","90 Years",{"count":110,"type":21},"This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.",[28,140,554],"Transplantation Infection",[556,140,557],"covid19","transplantation","2024-07-02",{"date":560,"type":38},"2024-07-03",{"date":562,"type":38},"2020-07-01",{"date":467,"type":21},{"name":181,"class":45},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":46},"100422000","residual-sars-cov-2-presence-in-the-respiratory-tract-and-lung-parenchyma-after-sars-cov-2-infection-or-covid-19-100422000","NCT04775134","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma","REASSURE","Inclusion Criteria:\n\n* Patient requires medically indicated pulmonary resection\n* Informed consent\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\u002FCOVID-19\n* No informed consent",{"count":574,"type":21},75,"The aim of this study is to confirm or rule out the residual presence and viability of SARS- CoV-2 in the respiratory tract and lung parenchyma of patients previously infected with SARS-CoV-2.\n\nPresence and viability of SARS-CoV-2 in lung tissue will be assessed with reverse transcriptase-polymerase chain reaction (PCR) and viral culture. The histological location of residual SARS-CoV-2 will be determined with fluorescence immunohistochemistry and single molecule fluorescence in situ hybridization, targeting viral proteins and RNA respectively.",[28],"2024-07-01",{"date":560,"type":38},{"date":580,"type":38},"2021-01-31",{"date":467,"type":21},{"name":181,"class":45},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":590,"maxAge":86,"enrollmentInfo":591,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":46},"100416724","comparison-of-the-immune-response-to-natural-covid-19-infection-and-vaccination-100416724","NCT04706390","Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination","COVID19vac-1","Inclusion Criteria:\n\n* subjects prioritized by national vaccination program\n\nExclusion Criteria:\n\n* Children\n* unable or unwilling to provide informed consent","20 Years",{"count":592,"type":21},2500,"The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or vaccines available to mitigate the pandemic. Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional marketing authorisation granted by the European Medicines Agency and further vaccine will be licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will recruit subjects who will be prioritised for vaccination with the primary aim of comparing the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2 and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples will be collected to evaluate the complications and kinetics, duration and breadth of the immune responses comparing natural infection to vaccination.",[28],[28,596,597],"Vaccine","SARS-CoV-2 antibody","2024-04-18",{"date":600,"type":38},"2024-04-19",{"date":602,"type":38},"2021-01-12",{"date":604,"type":21},"2030-12-12",{"name":606,"class":45},"University of Bergen",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":22,"phases":617,"briefSummary":618,"conditions":619,"keywords":620,"overallStatus":368,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":46},"100443922","phase-2-efesovir-fs-1-for-covid-19-phase-2-100443922","NCT05060705","\"Efesovir\" (FS-1) for COVID-19, Phase 2","Randomized Controlled Open Study of Safety and Preliminary Efficiency of the Drug \"Efesovir\" (Oral Solution) for Coronavirus Infection (COVID-19)","Inclusion Criteria:\n\n* polymerase chain reaction (PCR) confirmed coronavirus infection (COVID-19) in hospitalized patients with severe risk factors in age from 18 years to 59 years, of both sexes, irrespective of national or ethnic origin\n* the duration of the COVID-19 disease is no more than 10 days\n* informed concent to participate in clinical trials\n* informed concent to to use reliable contraceptive methods while participating in a clinical trial\n\nExclusion Criteria:\n\n* age less than 18 years old and over 59 years old\n* pregnancy or breastfeeding\n* hypersensitivity, allergy, intolerance to iodine, iodine-containing medicines\n* hypersensitivity to Remdesivir or its components\n* impaired consciousness, causing the impossibility of oral administration\n* conditions or circumstances that, in the opinion of the investigator, may affect the patient's safety or the quality of the results obtained\n* participation in another clinical trial, including in the period up to 2 months before this study\n* signs of multiple organ failure\n* alanine aminotransferase (ALT), aspartate aminotransferase (AST) is 5 or more times higher than normal\n* thrombocytopenia below 100 \\* 10\\^9\u002F l\n* decrease in glomerular filtration rate (GFR) less than 30 ml \u002F min by 1.73 m2\n* chronic heart failure with reduced ejection fraction\n* liver failure\n* coagulopathy\n* mechanical ventilation for 48 hours or more\n* extracorporeal membrane oxygenation (ECMO)\n* disseminated intravascular coagulation","59 Years",{"count":616,"type":21},62,[59],"Study of the efficacy and safety of the new drug \"Efesovir\" in comparison with the drug \"Remdesivir\" in the treatment of patients hospitalized with COVID-19.\n\nThe hypothesis of clinical study is the clinical efficacy of new drug \"Efesovir\" is 10% to 30% higher than of \"Remdesivir\".",[28],[266,621,622,623],"viral pneumonia","FS-1","Efesovir","2024-04-16",{"date":626,"type":38},"2024-04-17",{"date":628,"type":21},"2025-12",{"date":630,"type":21},"2026-11",{"name":632,"class":153},"Scientific Center for Anti-infectious Drugs, Kazakhstan"]